Pediatric Sarcoma in the Era of Precision Genomics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 3098
Special Issue Editors
2. Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3. In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
5. Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Interests: pediatric sarcoma; glioblastoma; precision genomics; biomarkers; combination therapy; DNA damage response/repair; replication stress; CHK1; BETs; CDK4/CDK6
Interests: Pediatric sarcoma; Precision genomics; Epigenetics; EZH2; Replication Stress; Systems biology; Biomarkers
Special Issue Information
Dear Colleagues,
Osteosarcoma (OS), Rhabdomyosarcoma (RMS) and the Ewing sarcoma family of tumors (ESFTs) are extremely rare sarcomas that globally affect children as well as adolescents and young adults (AYA). Lack of significant therapeutic advancements in aggressive sarcomas heightens the urgency to understand and target factors involved in the molecular pathogenesis of these diseases. Treatments deemed suitable for adult sarcoma patients may not always be appropriate for pediatric and AYA patients due to differences in tumor biology, genetic alterations, and drug pharmacokinetics. Moreover, with the low number of pediatric patients available to enroll in clinical trials, a targeted personalized approach offers new options that can potentially improve overall survival and quality of life. In the era of precision genomics, the ability to integrate patient history and outcome data linked to pre-clinical investigations provides opportunities to discover and validate novel therapeutic approaches for pediatric sarcomas that are efficacious and safe.
In this Special Issue, we focus on the use of precision genomics to interrogate biomarkers that are diagnostic, prognostic and/or predictors of therapeutic response in pediatric sarcoma. Functional validation of -OMICS data in relevant in-vitro and in-vivo models will contribute to our understanding of the molecular mechanisms involved in the pathogenesis of these sarcomas and help guide decisions on appropriate therapeutic interventions. Research articles and reviews focused on key pathways of dysregulation as well as preclinical modeling of pediatric sarcomas that evaluate aspects of tumor pathogenesis are encouraged. This includes studies focused on inter- and intra-genetic tumor heterogeneity, microenvironmental cues, metastatic potential, and therapeutic resistance mechanisms. Advancing our knowledge in these areas will be essential in our quest to discover improved treatment strategies and ultimately, a cure for aggressive sarcomas in children and AYA.
Prof. Dr. Karen E. Pollok
Prof. Dr. Pankita H. Pandya
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sarcomas
- pediatric sarcoma
- precision genomics
- biomarkers
- diagnostic and prognostic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
